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Anna S. F. Lok,1 and The U.S. HBV Epidemiology Study Group
Variants in the precore (G1896A) and core promoter (A1762T, G1764A) regions of hepatitis B virus
(HBV) may be related to serum HBV DNA levels and severity of liver disease. The aims of this
nationwide study were to determine the prevalence of HBV precore/core promoter variants in the
United States and the association between these variants and patient demographics, HBV geno-
types, serum HBV DNA level, and severity of liver disease. A total of 694 consecutive chronic
HBV-infected patients seen in 17 U.S. liver centers during a 1-year period were enrolled. Demo-
graphic, clinical, and laboratory data were collected. Sera were tested for HBV genotypes as well
as precore and core promoter variants by line-probe assays. Quantitative HBV DNA levels were
determined using Cobas Amplicor HBV Monitor kits. Precore and core promoter variants were
found in 27% and 44% of patients with chronic HBV infection in the United States. Precore and
core promoter variants were more common in hepatitis B e antigen (HBeAg)-negative than in
HBeAg-positive patients (precore, 38% vs. 9%; core promoter, 51% vs. 36%; respectively, P <
.001). The prevalence of these variants was related to ethnicity, place of birth, and HBV geno-
types. Patients with core promoter variants were more likely to have hepatic decompensation.
Precore and/or core promoter variants were associated with higher serum HBV DNA levels in
HBeAg-negative but not in HBeAg-positive patients. In conclusion, HBV precore and core
promoter variants are not rare in the United States. Physicians should be aware of the existence
of HBV precore and core promoter variants and the clinical condition of “HBeAg-negative
chronic hepatitis.” (HEPATOLOGY 2003;38:619-628.)
Hepatitis B virus (HBV) replicates asymmetri-cally via reverse transcription of an RNA inter-mediate,1 making it prone to mutations. The
most common naturally occurring HBV variants include
the precore stop codon mutation (G1896A), which abol-
ishes hepatitis B e antigen (HBeAg) production,2-4 and
the dual mutation in the core promoter region (A1762T,
G1764A), which down-regulates HBeAg production.5,6
These variants, particularly the precore variant, are found
in the vast majority of patients with HBeAg-negative
chronic hepatitis, in which HBV replication and hepatic
inflammation persist despite the absence of HBeAg. Pre-
core and core promoter variants have been reported in up
to 50% to 80% of patients with HBeAg-negative chronic
hepatitis B in Europe and Asia.7 Selection of precore vari-
ant is dependent on HBV genotype; it is most common in
patients with HBV genotype D and rare in patients with
HBV genotype A.8-11
The relationship between precore/core promoter vari-
ants, serum HBV DNA levels, and severity of liver disease
is unclear. Some5,12,13 but not all14 in vitro studies suggest
that core promoter mutations increase HBV replication.
One study using branched DNA assay found that serum
HBV DNA and alanine aminotransferase (ALT) levels
were comparable among patients with and without pre-
core/core promoter variants, regardless of HBeAg sta-
tus.15 Another study also using branched DNA assay
reported that the presence of precore/core promoter vari-
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ants was associated with lower serum HBV DNA levels,
but this study did not separately analyze HBeAg-positive
and HBeAg-negative patients.11 A third study based on
polymerase chain reaction assay found that among pa-
tients with severe HBeAg-negative hepatitis, those with
precore variant had higher HBV DNA levels compared
with patients with wild-type (WT) precore sequence.16
Precore/core promoter variants have been reported to be
associated with fulminant hepatitis,17-20 more active
chronic liver disease,4,8,9,21 and hepatocellular carci-
noma.22-24 However, other studies found that these vari-
ants can also be found in hepatitis B surface antigen car-
riers who had inactive liver disease.25,26 Thus, the
pathogenic roles of precore/core promoter variants and
their relationship to quantitative serum HBV DNA levels
need to be further examined.
To date, there are little data on the prevalence of pre-
core/core promoter variants in the United States. Previ-
ous small-scale studies suggest that precore variant as well
as HBeAg-negative chronic hepatitis B are rare in the
United States.27,28 The aims of this nationwide study were
to determine the prevalence of HBV precore/core pro-
moter variants in the United States and the association
between these variants and patient demographics, HBV
genotypes, serum quantitative HBV DNA level, and se-
verity of liver disease. The prevalence of HBV genotypes
in different regions of the United States and the relation
between HBV genotypes, mode of transmission, ethnic-
ity, and place of birth are separately reported.29
Patients and Methods
Patients. This was a cross-sectional study of adults
with chronic HBV infection in the United States. Con-
secutive chronic HBV-infected patients seen in 17 U.S.
liver centers during a 1-year period were enrolled. The 17
participating centers were distributed across the United
States. Patients currently receiving antiviral treatment
and those with recurrent hepatitis B after liver transplan-
tation were excluded. Patients on antiviral therapy were
excluded because of the effects of treatment on serum
HBV DNA levels and the possibility that antiviral therapy
might have an impact on precore/core promoter variants.
The protocol was approved by the institutional review
boards of each of the participating centers. Eligible pa-
tients were asked to sign a written consent form before
participating in this study.
Demographic, clinical, and laboratory data were col-
lected during clinic visits. The demographic data included
sex, age, place of birth, and ethnicity. The clinical infor-
mation included presumed source of infection, mode of
presentation (asymptomatic, symptoms of chronic liver
disease [such as fatigue, right upper abdominal discom-
fort], or decompensated cirrhosis [variceal hemorrhage,
ascites or hepatic encephalopathy]), liver histology, and
history of hepatitis B treatment. Laboratory results on
hepatitis B markers (hepatitis B surface antigen, HBeAg,
and hepatitis B e antibody), liver chemistry, platelet
count, and prothrombin time were also recorded. A
15-mL blood sample was collected during clinic visit, cen-
trifuged, aliquoted, and stored frozen at 20°C before
shipment to the central laboratory at the University of
Michigan.
HBV Genotyping. HBV genotyping was determined
by a line-probe assay (Inno-Lipa HBV genotyping assay;
Innogenetics Inc., Ghent, Belgium).11,30,31 All samples
with unclassified genotypes and 8% of samples that could
be genotyped were randomly selected and sent for bidi-
rectional automated sequencing at the DNA sequencing
core facility (University of Michigan Medical Center) us-
ing the standard protocol for the Applied Biosystems
DNA sequencer 377 (Perkin Elmer Corp., Foster City,
CA). Sequencing results were compared with published
sequences to ascertain HBV genotypes.32,33
Precore Stop Codon Variant (G1896A) and Core
Promoter Variant (A1762T, G1764A). Serum samples
were tested for precore stop codon (G1896A) and core
promoter (A1762T, G1764A) variants using Inno-Lipa pre-
core/core promoter kits (Innogenetics Inc.).11,30,31 Except
for the primers, the procedure was similar to that for HBV
genotyping. All samples with indeterminate results and
10% of randomly selected samples with precore and/or
core promoter variant were sent for direct sequencing as
previously described.
Quantification of Serum HBV DNA Levels. Serum
HBV DNA level was quantified by a polymerase chain
reaction assay with a lower limit of detection of 2  102
copies/mL and a linearity range of 2  102 to 2  105
copies/mL (Cobas Amplicor HBV Monitor; Roche Diag-
nostic Systems Inc., Pleasanton, CA).34-37 All samples
with positive HBeAg were prediluted up to 106 fold, and
a 105-fold dilution was used for initial testing. For sam-
ples with negative HBeAg, undiluted serum was used for
initial testing, retesting after dilution was performed
when results of the initial testing were greater than 1 
105 copies/mL.
Statistical Analyses. Results were expressed as
mean  SE. Data were analyzed using SPSS version 10.0
software package (SPSS Inc., Chicago, IL). Statistical
analyses were performed using 2 and Fisher’s exact test
for categorical variables. Independent t test or one-way
ANOVA with Tukey test were used for continuous vari-
ables as appropriate. Multivariate analyses with logistic
regression were used to determine the independent factors
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that correlate with serum quantitative HBV DNA level
and severity of liver disease. Results were considered sta-
tistically significant at P  .05.
Results
A total of 694 patients were enrolled. Serum HBV
DNA was detected in 530 patients (76%): 196 of 199
(98%) HBeAg-positive and 334 of 495 (68%) HBeAg-
negative patients. The mean age of these 530 patients was
43  1 years (range, 13-80 years), and 68% were men;
32% were non-Hispanic white, 9% black, 56% Asian,
and 3% of other races. Table 1 summarizes the compari-
son of patients with or without detectable serum HBV
DNA. Patients with detectable serum HBV DNA had
significantly higher prevalence of HBeAg and abnormal
ALT levels.
A total of 453 patients were excluded. The demograph-
ics of these patients were comparable to that of the pa-
tients enrolled. The mean age was 45  1 years, and 66%
were men; 34% were non-Hispanic white, 5% black,
56% Asian, and 5% of other races. The reasons for exclu-
sion included currently receiving antiviral therapy (69%),
refusal to participate (12%), prior liver transplantation
(4%), and poor venous access or blood sample not drawn
(15%). Of the patients who were excluded because they
were receiving antiviral treatment, approximately 75%
were HBeAg positive when treatment was initiated.
The prevalence of HBV genotypes in the study popu-
lation was as follows: A, 34.7%; B, 22.0%; C, 30.8%; D,
10.4%; E, 0.4%; F, 0.6%; G, 1.1%. All except 4 samples
(99%) could be genotyped by Inno-Lipa assay. Sequenc-
ing results of 53 randomly selected samples that could be
genotyped were completely concordant with the Inno-
Lipa assay.
Indeterminate results were obtained in 1.5% (n  8)
samples in the precore and 8.7% (n  46) in the core
promoter region using the Inno-Lipa assay. The main
reason for indeterminate results in the precore region was
due to a point mutation (G1897A) in the region of the
probe. Deletions (n  19), single rather than dual muta-
tions (A1762T or G1764A) (n  17), and other point mu-
tations in the region of the probe (n  10) were the main
reasons for indeterminate results in the core promoter
region. Of the samples that could be typed, the concor-
dance between the Inno-Lipa assay and sequencing was
99%. Line-probe assay was more sensitive in detecting
mixed sequences than direct sequencing.
Prevalence of Precore/Core Promoter Variants in
Relation to HBeAg Status. Precore (G1896A) variant was
found in 27% and core promoter (A1762T, G1764A) vari-
ant in 44% of the study population. Compared with
HBeAg-positive patients, HBeAg-negative patients were
more likely to have precore (38% vs. 9%, P  .001) or
core promoter variants (51% vs. 36%, P  .001). Muta-
tions in both precore and core promoter regions were
found in 4% of HBeAg-positive and 19% of HBeAg-
negative patients, respectively (P  .001). WT sequences
in both precore and core promoter regions were found in
57% of HBeAg-positive and 27% of HBeAg-negative pa-
tients, respectively (P  .001).
Prevalence of Precore/Core Promoter Variants in
Relation to HBV Genotypes. A strong correlation was
found between HBV genotypes and precore as well as core
promoter variants (P  .001) (Fig. 1). Patients with ge-
notype A were most likely to have WT sequence in both
precore and core promoter regions, whereas patients with
genotype D were most likely to have mutations in both
regions. Precore variant (alone or in combination with
core promoter variant) was most common among patients
with genotypes D (55%) and B (44%), followed by geno-
type C (22%), and very rare in patients with genotype A
(3%). Core promoter variant (alone or in combination with
precore variant) was more common among patients with
genotype C (60%), followed by genotype A (41%) and D
(40%), and less common in patients with genotype B (26%).
Despite differences in prevalence of HBV genotypes in
different regions of the United States, the prevalence of
precore as well as core promoter variants was similar
across the country. WT sequences in both precore and
core promoter regions ranged from 36% in the West to
37% in the East and Midwest to 43% in the South.
Prevalence of Precore/Core Promoter Variants in
Relation to Ethnicity and Place of Birth. The preva-
lence of precore variants was significantly related to the
ethnicity of the subjects (P  .01) (Fig. 2). Precore vari-
ants (alone or in combination with core promoter variant)
Table 1. Comparison Between Patients With or Without







Age (y) 43  1 44  1 NS
Male (%) 68 69 NS
Born in the United States (%) 35 36 NS
Ethnicity (W/A/B/O %) 32/56/9/3 28/53/13/6 NS
HBeAg positive (%) 37 2 .001
Abnormal ALT (%) 58 35 .001
ALT (IU/L) 105  9 46  4 .001
AST (IU/L) 81  7 43  3 .001
Albumin (g/dL) 3.9  0.3 4.0  0.4 NS
Total bilirubin (mg/dL) 1.2  0.1 1.0  0.1 NS
Platelet count (1,000 K/mm3) 187  4 192  7 NS
Prothrombin time (s) 12.5  0.1 12.6  0.2 NS
Abbreviations: NS, not significant; W, white; A, Asian; B, black; O, other; AST,
aspartate aminotransferase.
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were found in 32% of Asian patients, 19% of white pa-
tients, and only 6% of black patients. The prevalence of
core promoter variants (alone or in combination with
precore variants) was also lower among black patients
(31%), but the difference across the ethnic groups was less
marked, being present in 45% of Asian and white patients
(P  .96). Mutations in both precore and core promoter
regions were most common among Asian patients (17%)
and very rare in black patients (2%).
The prevalence of precore variants (P  .001) was also
related to place of birth. Precore variant was found in only
10% of patients born in the United States, 33% of those
born in East Asia, and 56% of those born in Europe.
Patients born in the United States were more likely to
Fig. 1. Prevalence of precore
(PC)/core promoter (CP) variants in
relation to HBV genotypes. Var, vari-
ant.
Fig. 2. Prevalence of precore
(PC)/core promoter (CP) variants in
relation to ethnicity. Var, variant.
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have WT sequence in both precore and core promoter
regions than those born outside the United States (51%
vs. 32%; P  .001).
Precore/Core Promoter Variants and Liver Dis-
ease. Patients with WT and variant precore/core pro-
moter sequences were comparable in age and sex (Table
2). Patients with core promoter variant alone or in asso-
ciation with precore variant were more likely to have de-
compensated cirrhosis (P  .05) (Table 2) and to have
lower platelet count (Fig. 3) compared with those with
precore variant only or WT sequence in both precore/core
promoter regions. Based on a blood test at a single time
point, there was no difference in liver chemistries among
the patients with different patterns of precore/core pro-
moter sequences (Table 2 and Fig. 4).
To determine if precore/core promoter variants were
related to liver disease, we used ALT level as a surrogate
marker of hepatic inflammation and platelet count
(150,000 mm3) as a surrogate marker of liver fibrosis.
Potential factors that may be related to ALT level and
platelet count, including sex, age (older than 40 years or
40 years or younger), ethnicity, HBV genotype, core pro-
moter variant, precore variant, liver chemistries, previous
antiviral therapy, and log10 HBV DNA level, were ana-
lyzed. Multivariate analyses with logistic regression iden-
tified male sex as the only predictor of abnormal serum
ALT level among HBeAg-positive patients and male sex
and high HBV DNA level (105 copies/mL) as predic-
tors among HBeAg-negative patients (Table 3). In
HBeAg-positive patients, older age and presence of core
promoter variants were independently associated with
lower platelet counts; in HBeAg-negative patients, older
age, aspartate aminotransferase level, and clinical evidence
of decompensated cirrhosis were predictors of lower plate-
let counts (Table 4).
Precore/Core Promoter Variants and Quantitative
Serum HBV DNA Levels. Serum HBV DNA levels
were significantly higher among the HBeAg-positive pa-
tients. Among the patients with detectable serum HBV
DNA, the mean level for HBeAg-positive patients was 3
log10 higher (mean  SEM, 8.0  0.1; median, 8.5;
range, 2.9-10.3 log10 copies/mL) than for HBeAg-nega-
tive patients (mean  SEM, 4.7  0.1; median, 4.4;
range, 2.4-10.0 log10 copies/mL) (P  .001). This differ-
ence was more marked when patients with undetectable
serum HBV DNA were included and an arbitrary value of
1 log10 copies/mL was assigned to those patients; the
mean HBV DNA level for HBeAg-positive patients was 4
log10 higher (mean  SEM, 7.9  0.1; median, 8.5;
range, 1.0-10.3 log10 copies/mL) than the HBeAg-nega-
tive patients (mean  SEM, 3.6  0.1; median, 3.6;
range, 1.0-10.0 log10 copies/mL) (P  .001).
HBeAg-positive patients with core promoter variant
had significantly lower serum HBV DNA levels com-
pared with those with WT sequence in the core promoter
region (Fig. 5A). The reverse was true among the HBeAg-
negative patients. HBeAg-negative patients with either
core promoter or precore variants had significantly higher











No. of patients 201 65 160 69 35
% of population 38 12 30 13 7
Male 139 (69) 49 (75) 104 (65) 46 (67) 23 (66) NS
Age (yr) 42  1 41  1 43  1 46  2 44  2 NS
Born in the United States 92 (46) 9 (14) 64 (40) 9 (13) 11 (31) .001
HBeAg positive 111 (55) 8 (12) 62 (39) 9 (13) 6 (17) .001
Abnormal ALT level 122 (61) 35 (55) 93 (58) 33 (48) 24 (69) NS
Decompensated cirrhosis 14 (7) 4 (6) 24 (15) 9 (13) 6 (17) .08
Liver biopsy within past 2 y 69 (34) 19 (29) 73 (46) 18 (26) 16 (46) NS
Biopsy-proven cirrhosis
(cirrhosis/biopsies)
23 (34) 5 (28) 27 (38) 8 (44) 5 (31) NS
Prior antiviral treatment 40 (20) 13 (20) 40 (25) 11 (16) 6 (17) NS
Response to previous
antiviral treatment
9 (23) 1 (9) 12 (35) 1 (9) 2 (40) NS
ALT (IU/L) 123  20 133  35 80  9 77  11 110  24 NS
AST (IU/L) 93  14 83  20 73  8 60  6 78  12 NS
Albumin (g/dL) 3.9  0.1 4.0  0.1 3.8  0.1 3.8  0.1 3.8  0.1 NS
Total bilirubin (mg/dL) 1.1  0.1 1.4  0.3 1.2  0.2 1.5  0.3 0.9  0.1 NS
Platelet count (K/mm3) 203  6 202  9 171  6 167  10 178  13 .05
Prothrombin time (s) 12.3  0.2 12.1  0.2 12.8  0.3 13.1  0.4 11.9  0.3 NS
NOTE. Results of continuous variables are expressed as mean  SEM, and results of categorical variables are expressed as number (%). Response to prior antiviral
treatment could only be obtained in 100 of 110 patients.
Abbreviations: CP, core promoter; PC, precore; Var, variant; NS, not significant; AST, aspartate aminotransferase.
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HBV DNA levels compared with those with WT se-
quence in both precore/core promoter regions (Fig. 5B).
Potential factors that may be related to serum HBV
DNA levels, including sex, age, ethnicity, HBV genotype,
precore/core promoter variant, previous antiviral therapy,
liver chemistries, and hepatic decompensation, were ana-
lyzed. Multivariate analysis with logistic regression iden-
tified compensated liver disease, WT sequence in the core
promoter region, and age younger than 40 years as pre-
dictors of higher serum HBV DNA level among HBeAg-
positive patients, whereas abnormal ALT levels and the
presence of core promoter or precore variant were predic-
tors of higher serum HBV DNA level among HBeAg-
negative patients (Table 5). HBV genotype was not
related to serum HBV DNA level among HBeAg-positive
as well as HBeAg-negative patients.
Discussion
In this study, precore and core promoter variants were
found in 27% and 44%, respectively, of patients with
chronic HBV infection in the United States. Several fac-
tors may account for the higher prevalence of precore and
core promoter variants in our study compared with earlier
studies.27,28 First, the influx of immigrants from countries
with a high prevalence of precore and core promoter vari-
ants in recent years may have altered the epidemiology of
HBV infection in this country. This was supported by the
fact that precore variant was found in only 10% of the
patients born in the United States but in 36% of those
born outside this country. Second, our study included a
larger number of patients from different regions of the
Fig. 4. Relationship between different precore (PC)/core promoter
(CP) patterns and serum ALT value in (A) HBeAg-positive and (B)
HBeAg-negative patients. The box plots show the 10th, 25th, 50th, 75th,
and 90th percentiles and outliers (circles). Mean HBV DNA level is
indicated as a dotted line. Var, variant.
Fig. 3. Relationship between different precore (PC)/core promoter
(CP) patterns and platelet count in (A) HBeAg-positive and (B) HBeAg-
negative patients. The box plots show the 10th, 25th, 50th, 75th, and
90th percentiles and outliers (circles). Mean HBV DNA level is indicated
as a dotted line. Var, variant.
624 CHU ET AL. HEPATOLOGY, September 2003
United States. Third, it is possible that differences in
pathogenicity and responsiveness to treatment may have
resulted in global changes in the prevalence of precore/
core promoter variants over time. Finally, the exclusion of
patients currently receiving antiviral treatment, most of
whom were HBeAg positive, may have resulted in a bias
toward HBeAg-negative patients, who are more likely to
harbor these variants.
We acknowledge that enrollment of patients from ter-
tiary care liver centers and exclusion of patients currently
receiving antiviral therapy may have introduced selection
bias and our results may not be generalized to all patients
with chronic HBV infection in the United States. The
most common reason for exclusion was current antiviral
therapy, and approximately 75% of patients currently re-
ceiving antiviral therapy were HBeAg positive. The dis-
proportionate exclusion of HBeAg-positive patients
might have resulted in an overestimation of precore and,
to a lesser extent, core promoter variants. It is also possible
that patients with more active liver disease may have been
disproportionately excluded. However, this is the largest
cross-sectional study of the prevalence and clinical signif-
icance of precore/core promoter variants in the United
States. Our study represents the first step toward under-
standing the molecular epidemiology of HBV infection in
this country.
In accordance with previous reports, our study showed
that precore variants were predominantly detected in
HBeAg-negative patients, whereas core promoter variants
were found in both HBeAg-negative and HBeAg-positive
patients.15,38 A more marked increase in the prevalence of
precore versus core promoter variants in HBeAg-negative
patients is attributed to the fact that precore (G1896A)
variants abolish whereas core promoter variants (A1762T,
G1764A) only down-regulate HBeAg production.
We confirmed the strong relationship between precore
variant and HBV genotypes.8-11 We found that core pro-
moter variant was more evenly distributed among the 4
major HBV genotypes. Nevertheless, as in our previous
study,29 core promoter variants tended to be more preva-
lent among HBV genotypes (A and C) that are less often
associated with precore variants. The association between
HBV genotypes and precore (G1896A) variant is related to
base pairing in the stem-loop structure of the pregenome
encapsidation sequence,10,11,39,40 but the basis for the as-
Table 3. Independent Factors Associated With Abnormal
Serum ALT (>45 IU/L)
Factors Odds Ratio 95% CI P
HBeAg-positive patients
Male sex 4.28 2.00-9.17 .001
HBeAg-negative patients
Serum HBV DNA 105 copies/mL 6.16 3.59-10.56 .001
Male sex 2.09 1.19-3.66 .01
Table 4. Independent Factors Associated With Lower
Platelet Count (<150,000/mm3)
Factors Odds Ratio 95% CI P
HBeAg-positive patients
Age 40 years 4.95 2.41-10.16 .001
With CP variant 2.89 1.43-5.86 .003
HBeAg-negative patients
Decompensated cirrhosis 11.16 4.33-28.78 .001
Age 40 years 3.40 1.75-6.58 .001
Abnormal AST level 2.32 1.31-4.09 .024
Abbreviation: CP, core promoter; AST, aspartate aminotransferase.
Fig. 5. Relationship between different precore (PC)/core promoter
(CP) patterns and serum HBV DNA level (log10 copies/mL) in (A)
HBeAg-positive and (B) HBeAg-negative patients. The box plots show the
10th, 25th, 50th, 75th, and 90th percentiles and outliers (circles).
Mean HBV DNA level is indicated as a dotted line. Var, variant.
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sociation between HBV genotypes and core promoter
variants has not been deciphered.
The clinical significance of precore and core promoter
variants is not yet fully understood. We analyzed our data
of a large number of unselected patients to determine if
precore and core promoter variants are associated with
more active or advanced liver disease. Based on blood tests
at a single time point, we found no difference in liver
chemistries between patients with WT versus variant pre-
core/core promoter sequences. We acknowledge that pa-
tients with chronic hepatitis B may have fluctuating
serum aminotransferase levels, and liver chemistries may
not accurately reflect hepatic necroinflammation.4,41,42
Thus, a blood test at a single time point cannot defini-
tively exclude a relationship between precore/core pro-
moter variants and activity of liver disease. Our study did
show a correlation between core promoter variant and
advanced liver disease (cirrhosis and hepatic decompensa-
tion). We found that patients with core promoter variant
alone or in association with precore variant were more
likely to have decompensated cirrhosis (defined as current
or previous history of variceal hemorrhage, ascites, or he-
patic encephalopathy) compared with those with precore
variant only or WT sequence in both precore/core pro-
moter regions. In addition, other than age, core promoter
variant was independently associated with low platelet
count, a reliable predictor of liver fibrosis, in HBeAg-
positive patients.
In this study, we found no correlation between ALT
and serum HBV DNA levels among HBeAg-positive pa-
tients. This may be related to the high percentage of Asian
patients, many of whom may be in the immune-tolerant
phase.43,44 However, high serum HBV DNA level was the
most important predictor of abnormal ALT values among
HBeAg-negative patients. Lindh et al.16 also reported an
association between serum HBV DNA level and histo-
logic inflammation and fibrosis scores and ALT values in
HBeAg-negative but not HBeAg-positive patients. These
findings suggest that the mechanisms of liver damage may
be different in HBeAg-positive and in HBeAg-negative
chronic hepatitis, with host immune response more im-
portant in HBeAg-positive patients and direct viral effects
in HBeAg-negative patients.
Our study showed that HBeAg-positive patients with
selection of core promoter variants had lower serum HBV
DNA levels, whereas HBeAg-negative patients with core
promoter or precore variants had higher serum HBV
DNA levels compared with those with WT sequence in
both precore and core promoter regions. The discrepant
effects of precore/core promoter mutation on serum HBV
DNA levels in HBeAg-positive versus HBeAg-negative
patients may be related to the modulating effect of the
host immune response. During the HBeAg-positive
phase, selection of core promoter variant occurs during
the process of immune clearance, accounting for the lower
serum HBV DNA levels. After HBeAg seroconversion,
there is an overall 3 to 4 log10 reduction in serum HBV
DNA levels.31 HBeAg-negative patients with WT se-
quence in both the precore and core promoter regions
have lower serum HBV DNA levels because virus replica-
tion is adequately suppressed by the host immune system,
whereas HBeAg-negative patients with core promoter or
precore variants have higher serum HBV DNA levels be-
cause HBV variants with deficient HBeAg production
can evade host immune response and are therefore able to
maintain higher levels of HBV replication. We acknowl-
edge that our observation was based on serum HBV DNA
levels at a single time point and that patients with chronic
hepatitis B, particularly HBeAg-negative patients, tend to
have fluctuating serum HBV DNA levels. Nevertheless,
compared with other reports, our study included the larg-
est number of patients and used a sensitive polymerase
chain reaction assay to quantify serum HBV DNA levels.
In summary, our nationwide study showed that pre-
core and core promoter variants could be found in ap-
proximately one third of patients with chronic HBV
infection in the United States. The prevalence of these
variants was related to ethnicity, place of birth, and HBV
genotypes. Nevertheless, precore as well as core promoter
variants were detected at similar rates across the country.
Our study also showed that patients with core promoter
variants were more likely to have cirrhosis and hepatic
decompensation. In addition, HBeAg-negative patients
with core promoter and/or precore variants had higher
serum HBV DNA levels than those with WT sequence.
Thus, physicians practicing in the United States should be
aware of the existence of HBV precore and core promoter
variants and the clinical condition “HBeAg-negative
Table 5. Independent Factors Associated With Higher Serum
HBV DNA Level in HBeAg-Positive (>108 copies/mL) and
HBeAg-Negative Patients (>105 copies/mL)
Factors Odds Ratio 95% CI P
HBeAg-positive patients
Without CP variant 3.55 1.67-7.53 .001
Compensated liver disease 4.74 1.36-16.55 .015
Age 40 years 2.49 1.14-5.42 .022
HBeAg-negative patients
Abnormal ALT level 5.49 2.80-10.73 .001
With CP variant 3.42 1.90-6.16 .001
With PC variant 1.87 1.05-3.32 .032
NOTE. Different cutoffs in serum HBV DNA levels were used for analysis because
HBeAg-positive patients had serum HBV DNA levels that were 3-4 log10 higher
than HBeAg-negative patients.
Abbreviations: CP, core promoter; PC, precore.
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chronic hepatitis” because the diagnosis, natural course,
and treatment of this condition differs from classic
“HBeAg-positive chronic hepatitis.” At the moment, the
clinical entity “HBeAg-negative chronic hepatitis” can be
diagnosed by the absence of HBeAg, presence of hepatitis
B e antibody, serum HBV DNA level greater than 5 log10
copies/mL, and biochemical/histologic evidence of active
liver disease. Further studies are needed to determine if
additional testing for HBV genotype as well as precore
and core promoter variants will help in prognostication
and in guiding treatment decisions.
Acknowledgment: The authors thank the investiga-
tors and study coordinators at the participating centers for
their assistance in data and sample collection: Cleveland
Clinic: William Carey and Marcia Grealis; Columbia-
Presbyterian Medical Center: Robert Brown, Jr., Mich-
elle Lai, and Anna Lang; Indiana University: Paul Kwo;
Inova Fairfax Hospital: Zobair Younossi, Terri Martin,
and Renee Brenner; Mayo Clinic, Rochester: Russell
Wiesner and Michael Ishitani; Virginia Commonwealth
University: Velimir Luketic and Denice Shelton; Mount
Sinai Medical Center: Albert D. Min and Jessica Korman;
Ochsner Clinic: Robert Perrillo and Melissa Wiseman;
Rush University: Donald Jensen and Mary Vance; Stan-
ford University: Emmet Keeffe and Suzanna Lam; St.
Louis University: Adrian DiBisceglie and Patricia Os-
mack; UCLA: Steven-Huy Han and Val Peacock; UCSF:
Norah Terrault and Karly Louie; University of Florida:
Consuelo Soldevila-Pico; University of Miami: Rajender
Reddy and Maria Torres; University of Virginia: Timothy
Pruett, Robb McGory, and Terry Ryan; University of
Michigan: Anna S. F. Lok, Chi-Jen Chu, Robert Fontana,
Jorge Marrero, Grace Su, and Hari Conjeevaram.
References
1. Summers J, Mason WS. Replication of the genome of a hepatitis B-like
virus by reverse transcription of an RNA intermediate. Cell 1982;29:403-
415.
2. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ,
Markis A, Thomas HC. Mutation preventing formation of hepatitis B e
antigen in patients with chronic hepatitis B infection. Lancet 1989;2:588-
591.
3. Akahane Y, Yamanaka T, Suzuki H, Sugai Y, Tsuda F, Yotsumoto S,
Omi S, et al. Chronic active hepatitis with hepatitis B virus DNA and
antibody against e antigen in the serum. Disturbed synthesis and secretion
of e antigen from hepatocytes due to a point mutation in the precore
region. Gastroenterology 1990;99:1113-1119.
4. Brunetto MR, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A,
Serrano G, et al. Wild-type and e antigen-minus hepatitis B viruses and
course of chronic hepatitis. Proc Natl Acad Sci U S A 1991;88:4186-4190.
5. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally
occurring mutation in the hepatitis B virus basal core promoter on precore
gene expression and viral replication. J Virol 1996;70:5845-5851.
6. Scaglioni PP, Melegari M, Wands JR. Biologic properties of hepatitis B
viral genomes with mutations in the precore promoter and precore open
reading frame. Virology 1997;233:374-381.
7. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-
negative chronic hepatitis B and associated with precore and core promoter
variants. J Viral Hepat 2002;9:52-61.
8. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter
mutations and genotypes in relation to viral replication and liver damage in
East Asian hepatitis B virus carriers. J Infect Dis 1999;179:775-782.
9. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T,
Okanoue T, et al. A case-control study for clinical and molecular biological
differences between hepatitis B viruses of genotype B and C. HEPATOLOGY
2001;33:218-223.
10. Rodriguez-Frias F, Buti M, Jardi R, Cotrina M, Viladomiu L, Esteban R,
Guardia J. Hepatitis B virus infection: precore mutants and its relation to
viral genotypes and core mutations. HEPATOLOGY 1995;22:1641-1647.
11. Grandjacques C, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud
C, Maisonnas M, et al. Rapid detection of genotypes and mutations in the
pre-core promoter and the pre-core region of hepatitis B virus genome:
correlation with viral persistence and disease severity. J Hepatol 2000;33:
430-439.
12. Moriyama K, Okamoto H, Tsuda F, Mayumi M. Reduced precore tran-
scription and enhanced core-progenome transcription of hepatitis B virus
DNA after replacement of the precore-core promoter with sequences asso-
ciated with e antigen-seronegative persistent infections. Virology 1996;
226:269-280.
13. Buckwold VE, Xu Z, Yen TS, Ou JH. Effects of a frequent double-nucle-
otide basal core promoter mutation and its putative single-nucleotide pre-
cursor mutations on hepatitis B virus gene expression and replication.
J Gen Virol 1997;78:2055-2065.
14. Gunther S, Piwon N, Will H. Wild-type levels of pregenomic RNA and
replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B
virus with C(1653)3 T, A(1762)3 T and G(1764)3 A mutations in
the core promoter. J Gen Virol 1998;79:375-380.
15. Chan, HL Leung NW, Hussain M, Wong ML, Lok AS. Hepatitis B e
antigen-negative chronic hepatitis B in Hong Kong. HEPATOLOGY 2000;
31:763-768.
16. Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels,
precore mutations, genotypes and histological activity in chronic hepatitis
B. J Viral Hepat 2000;7:258-267.
17. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B
virus mutant associated with an epidemic of fulminant hepatitis. N Engl
J Med 1991;324:1705-1709.
18. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the
precore region of hepatitis B virus DNA in patients with fulminant and
severe hepatitis. N Engl J Med 1991;324:1699-1704.
19. Hasegawa K, Huang J, Wands JR, Obata H, Liang TJ. Association of
hepatitis B viral precore mutations with fulminant hepatitis B in Japan.
Virology 1991;185:460-463.
20. Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K,
Tsuda F, et al. Hepatitis B virus strains with mutations in the core promo-
tor in patients with fulminant hepatitis. Ann Intern Med 1995;122:241-
248.
21. Takahashi K, Aoyama K, Ohno N, Iwata K, Akahane Y, Baba K, Yo-
shizawa H, et al. The precore/core promoter mutant (T1762A1764) of
hepatitis B virus: clinical significance and an easy method for detection.
J Gen Virol 1995;76:3159-3164.
22. Baptista M, Kramvis A, Kew MC. High prevalence of 1762T 1764A
mutations in the basal core promoter of hepatitis B virus isolated from
Black Africans with hepatocellular carcinoma compared with symptomatic
carriers. HEPATOLOGY 1999;29:946-953.
23. Fang ZL, Ling R, Wang SS, Nong J, Huang CS, Harrison TJ. HBV core
promoter mutations prevail in patients with hepatocellular carcinoma
from Guangxi, China. J Med Virol 1998;56:18-24.
24. Zhong S, Chan JY, Yeo W, Tam JS, Johnson PJ. Frequent integration of
precore/core mutants of hepatitis B virus in human hepatocellular carci-
noma tissue. J Viral Hepat 2000;7:115-123.
25. Naoumov NV, Schneider R, Grotzinger T, Jung MC, Miska S, Pape GR,
Will H. Precore mutant hepatitis B virus infection and liver disease. Gas-
troenterology 1992;102:538-543.
HEPATOLOGY, Vol. 38, No. 3, 2003 CHU ET AL. 627
26. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K,
Tanaka T, et al. Hepatitis B virus with mutations in the core promoter for
an e antigen-negative phenotype in carriers with antibody to e antigen.
J Virol 1994;68:8102-8110.
27. Mangia A, Chung YH, Hoofnagle JH, Birkenmeyer L, Mushahwar I, Di
Bisceglie AM. Pathogenesis of chronic liver disease in patients with chronic
hepatitis B virus infection without serum HBeAg. Dig Dis Sci 1996;41:
2447-2452.
28. Gray AH, Fang JW, Davis GL, Mizokami M, Wu PC, Williams R, Schuster
SM, et al. Variations of hepatitis B virus core gene sequence in Western pa-
tients with chronic hepatitis B virus infection. J Viral Hepat 1997;4:371-378.
29. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C,
Carey W, et al, and the U.S. HBV Epidemiology Study Group. Hepatitis
B virus genotypes in the United States: results of a nationwide study.
Gastroenterology 2003 (In press).
30. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated
with earlier HBeAg seroconversion compared to hepatitis B virus genotype
C. Gastroenterology 2002;122:1756-1762.
31. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during
different stages of chronic hepatitis B infection. HEPATOLOGY 2002;36:
1408-1415.
32. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic
relatedness, and structural proteins of six strains of the hepatitis B virus,
four of which represent two new genotypes. Virology 1994;198:489-503.
33. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF,
Rossau R. A new genotype of hepatitis B virus: complete genome and
phylogenetic relatedness. J Gen Virol 2000;81:67-74.
34. Gerken G, Gomes J, Lampertico P, Colombo M, Rothaar T, Trippler M,
Colucci G. Clinical evaluation and applications of the Amplicor HBV
Monitor test, a quantitative HBV DNA PCR assay. J Virol Methods 1998;
74:155-165.
35. Kessler HH, Preininger S, Stelzl E, Daghofer E, Santner BI, Marth E,
Lackner H, et al. Identification of different states of hepatitis B virus
infection with a quantitative PCR assay. Clin Diagn Lab Immun 2000;7:
298-300.
36. Noborg U, Gusdal A, Pisa EK, Hedrum A, Lindh M. Automated quanti-
tative analysis of hepatitis B virus DNA by using the Cobas Amplicor HBV
Monitor test. J Clin Microbiol 1999;37:2793-2797.
37. Pawlotsky JM, Bastie A, Hezode C, Lonjon I, Darthuy F, Remire J,
Dhumeaux D. Routine detection and quantification of hepatitis B virus
DNA in clinical laboratories: performance of three commercial assays.
J Virol Methods 2000;85:11-21.
38. Kidd-Ljunggren K, Oberg M, Kidd AH. Hepatitis B virus X gene 1751 to
1764 mutations: implications for HBeAg status and disease. J Gen Virol
1997;78:1469-1478.
39. Junker-Niepmann M, Bartenschlager R, Schaller H. A short cis-acting
sequence is required for hepatitis B virus pregenome encapsidation and
sufficient for packaging of foreign RNA. EMBO J 1990;9:3389-3396.
40. Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis
B virus serve to enhance the stability of the secondary structure of the
pre-genome encapsidation signal. Proc Natl Acad Sci USA 1994;91:4077-
4081.
41. Zarski JP, Marcellin P, Cohard M, Lutz JM, Bouche C, Rais A. Com-
parison of anti-HBe-positive and HBe-antigen-positive chronic hepa-
titis B in France. French Multicentre Group. J Hepatol 1994;20:636-
640.
42. Hadziyannis SJ, Vassilopoulos D. Hepatitis e antigen-negative chronic
hepatitis B. HEPATOLOGY 2001;34:617-624.
43. Chu CM, Karyannis P, Fowler MJF, Monjardino J, Liaw YF, Thomas HC.
Natural history of chronic hepatitis B virus infection in Taiwan: studies of
HBV DNA in serum. HEPATOLOGY 1985;5:431-434.
44. Lok AS. Natural history and control of perinatally acquired hepatitis B
virus infection. Dig Dis 1992;10:46-52.
628 CHU ET AL. HEPATOLOGY, September 2003
